2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Does hypertension impact 24-hour urine parameters in patients with nephrolithiasis? - Session Highlights

ORLANDO, FL USA (UroToday.com) - There is a known association between hypertension (HTN) and nephrolithiasis. Abnormalities in renal calcium metabolism in hypertensive patients can lead to increased urinary calcium excretion. The research group sought to evaluate differences in 24-hour urine parameters between patients with and without HTN in a large cohort of stone formers.

auaThis retrospective study consisted of patients with a 24-hour urinalysis (Litholink®) available, and a history of HTN in the demographic data. Univariate t test and multivariate analysis were performed comparing the 24-hour urinalysis profiles of patients with HTN to that of normotensive patients.

A total of 1 115 patients were included, 442 (40%) had HTN and 673 (60%) did not. Univariate analysis revealed significantly greater urine sodium and potassium (p < 0.05), and significantly lower urine pH, calcium, supersaturation (SS) of calcium oxalate (CaOx) and SS calcium phosphate (all p < 0.05) in hypertensive patients. Multivariate analysis showed significantly lower calcium (mean difference=-20.13), citrate (-74.04), phosphate (-0.043), and SS CaOx (-0.648) in patients with HTN.

The research group showed significant lowered 24-hour urine calcium and SS CaOx in hypertensive patients on both univariate and multivariate analyses. In addition, they demonstrated significantly lower 24-hour urine citrate on multivariate analysis.

In conclusion, lower levels of stone inhibitors such as citrate may play a greater role in stone formation in patients with hypertension than deranged calcium metabolism. This finding might help the mitigation of nephrolithiasis in hypertensive patients.

Presented by Christopher Hartman, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

New Hyde Park, NY USA

Written by Achim Lusch, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe